The DOI matches its Crossref record.
Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial
Open accessAbstract
Increased tumour necrosis factor-α levels have been observed in bronchial biopsies and induced sputum from subjects with severe asthma. We investigated etanercept (ETN) as a therapeutic option for treating moderate-to-severe persistent asthma. In this 12-week, randomised, double-blind, placebo-controlled, phase 2 trial, subjects (n = 132) with moderate-to-severe persistent asthma received subcutaneous injections of 25 mg ETN or placebo twice weekly, and were evaluated at baseline, and at weeks 2, 4, 8 and 12. The primary end-point was the change from baseline to week 12 in pre-bronchodilator forced expiratory volume in 1 s (FEV 1) % predicted. Secondary end-points included morning peak expiratory flow, FEV 1% pred, Asthma Control Questionnaire (5-item version), asthma exacerbations, provocative concentration of methacholine causing a 20% decrease in FEV 1, and the Asthma Quality of Life Questionnaire. No significant differences were observed between ETN and placebo for any of the efficacy end-points. ETN treatment was well tolerated, with no unexpected safety findings observed during the study. Clinical efficacy of ETN was not shown in subjects with moderate-to-severe persistent asthma over 12 weeks. However, ETN treatment was a well-tolerated therapy. Studies in specific subsets of patients with asthma with longer-term follow-up may be needed to fully evaluate the clinical efficacy of ETN in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Neutrophilic Inflammation in Asthma and Association with Disease Severity
Ray, A., & Kolls, J. K. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.07.003 · Cited by 546
Eosinophilic and Noneosinophilic Asthma
Carr, T. F., Zeki, A. A., & Kraft, M. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201611-2232pp · Cited by 351
Mechanisms and therapeutic strategies for non‐T2 asthma
Sze, E., Bhalla, A., & Nair, P. (2020) · Allergy · doi:10.1111/all.13985 · Cited by 259
Severe asthma: Advances in current management and future therapy
Barnes, P. J. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.11.006 · Cited by 174
Novel Biologicals for the Treatment of Allergic Diseases and Asthma
Tan, H.-T. T., Sugita, K., & Akdis, C. A. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0650-5 · Cited by 68
Metadata
- Authors
- Holgate, S. T., Noonan, M., Chanez, P., Busse, W., Dupont, L., Pavord, I., Hakulinen, A., Paolozzi, L., Wajdula, J., Zang, C., Nelson, H., & Raible, D.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2010-11-25
- Volume
- 37
- Issue
- 6
- Pages
- 1352-1359
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2170711652
- Cited by
- 168
- References
- 0
- FWCI
- 7.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. https://app.cochat.ai/papers/10.1183/09031936.00063510
- The paper
- Holgate, S. T., Noonan, M., Chanez, P., Busse, W., Dupont, L., Pavord, I., Hakulinen, A., Paolozzi, L., Wajdula, J., Zang, C., Nelson, H., & Raible, D. (2011). Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. European Respiratory Journal. https://doi.org/10.1183/09031936.00063510
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.